Thanks to Slack for supporting Motley Full Industry Focus.

Slack is a collaboration hub that lets you organize your team's work into channels

where everyone is included. Relevant information is in one place

and new team members can easily get up to speed.

Learn more at slack.com.

Welcome to Industry Focus, the podcast that dives into a different sector of the

stock market every day.

It's Wednesday, April 11th, as Shannon will point out to you, my birthday, and we've got a roundup of two big news stories, a phase 3 flop with major

implications across biotech and a big buyout.

This is Michael Douglas, your intrepid financials host and past health care host,

filling in for Christine Harges, who is taking a well-deserved vacation.

And we just decided to change everything up for this episode because Todd Campbell is not calling in either.

Instead, I'm joined in the studio by health care analyst Shannon Jones who is making her industry focus debut,

so please welcome her with me to the show Shannon welcome it's good to have you

Michael thank you so much I am so excited it's a bit surreal to be sitting in here

with you on your birthday I consider it a privilege and honor.

Thank you for that opportunity.

Sure, I'm certainly excited to have you in while I'm subbing for Christine.

So let's talk about our two big news items and truthfully did not oversell these.

I think they're pretty major. So the first one, Insight had a major drug

flop. Let's talk about that a little bit.

And I would even say major drug flop is probably an understatement at this point. This was and probably

...